Trial Profile
Phase II study of sunitinib malate (SUTENT®) in relapsed germ cell tumors in males.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Mar 2017
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Germ cell and embryonal neoplasms; Germ cell cancer
- Focus Therapeutic Use
- 02 Mar 2017 New trial record